| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Bexarotene | CTRPv2 | pan-cancer | AAC | -0.009 | 0.8 |
| mRNA | tandutinib | CTRPv2 | pan-cancer | AAC | -0.009 | 0.8 |
| mRNA | TAE684 | GDSC1000 | pan-cancer | AAC | -0.014 | 0.8 |
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.008 | 0.8 |
| mRNA | Nutlin-3a (-) | GDSC1000 | pan-cancer | AAC | -0.0087 | 0.8 |
| mRNA | TAE684 | CTRPv2 | pan-cancer | AAC | 0.0085 | 0.8 |
| mRNA | foretinib | CTRPv2 | pan-cancer | AAC | 0.0084 | 0.8 |
| mRNA | SCH-529074 | CTRPv2 | pan-cancer | AAC | -0.0091 | 0.8 |
| mRNA | Compound 7d-cis | CTRPv2 | pan-cancer | AAC | -0.0088 | 0.8 |
| mRNA | MK 1775 | CTRPv2 | pan-cancer | AAC | -0.008 | 0.8 |